Inogen (NASDAQ: INGN) reported Q1 EPS of $0.11, may not compare to the analyst estimate of $0.12. Revenue for the quarter came in at $43 million versus the consensus estimate of $41.75 million.

Financial Outlook for 2016

The Company confirmed its 2016 revenue guidance of $187 to $191 million, which represents year-over-year growth of 17.6% to 20.1%. The Company continues to expect total revenue headwind from Medicare competitive bidding reimbursement reductions to be 3.5 – 4.0% in 2016.

Inogen confirmed its 2016 Adjusted EBITDA estimate to be $37 to $39 million, representing an increase of 14.6% to 20.7% over 2015 and its Adjusted net income to be in the range of $12 to $14 million, representing 19.8% to 39.8% growth over 2015.

The Company confirmed its net income estimate in the range of $12 to $14 million, representing 3.6% to 20.8% growth over 2015.

In 2015, the Company experienced tax benefit adjustments of $1.6 million that are not expected to recur in 2016. Inogen expects an effective tax rate in 2016 of 35% or less compared to an effective tax rate of 32.0% in 2015, excluding the tax benefit adjustments, but the actual effective tax rate may vary depending on a variety of factors, such as actual disqualifying dispositions that occur within the year. Inogen expects a higher effective tax rate primarily due to lower tax deductions for equity compensation as a percentage of pre-tax income which is not expected to have as much of an impact on the 2016 effective tax rate as it did on the 2015 effective tax rate. The Company also expects the effective tax rate to fluctuate depending on disqualifying dispositions incurred within the respective quarters.

Inogen confirmed its expectation for net positive cash flow for 2016 with no additional equity capital required to meet its current operating plan.

For earnings history and earnings-related data on Inogen (INGN) click here.